تحميل...

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

Anti-PD-L1 antibodies inhibit interactions between PD-L1 and PD-1 and interactions between PD-L1 and B7-1, thereby reinvigorating anticancer immunity. Although there are numerous ongoing clinical studies evaluating combinations of standard chemotherapies and anti-PD-L1 antibodies, irinotecan has not...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Oncotarget
المؤلفون الرئيسيون:	Iwai, Toshiki, Sugimoto, Masamichi, Wakita, Daiko, Yorozu, Keigo, Kurasawa, Mitsue, Yamamoto, Kaname
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Impact Journals LLC 2018
الموضوعات:	Research Paper
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6101148/ https://ncbi.nlm.nih.gov/pubmed/30140379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25830
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies

مواد مشابهة